Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study

Real-World Data of Trifluridine/Tipiracil for Patients With Advanced Gastric Cancer: A Multi-Institutional Retrospective Study

Background: A trial with trifluridine/tipiracil (FTD/TPI) versus placebo in patients with heavily pretreated metastatic gastric cancer showed that FTD/TPI is effective with manageable toxicity in these patients. However, real-world data on the effects of FTD/TPI in patients with advanced gastric can...

Full description

Bibliographic Details
Main Authors:	Toshihiko Matsumoto, Shogo Yamamura, Tatsuki Ikoma, Yusuke Kurioka, Keitaro Doi, Tomoyo Yasuda, Shogen Boku, Takashi Kawai, Nobuhiro Shibata, Hiroki Nagai, Takao Tsuduki, Takanobu Shimada, Yusuke Matsumoto, Takehiko Tsumura, Masahiro Takatani, Hisateru Yasui, Hironaga Satake
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-11-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	https://doi.org/10.1177/11795549221137135

Similar Items

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab
by: Toshihiko Matsumoto, et al.
Published: (2023-02-01)

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
by: Toshihiko Matsumoto, et al.
Published: (2022-04-01)

Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab
by: Toshihiko Matsumoto, et al.
Published: (2023-07-01)

Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
by: Tatsuki Ikoma, et al.
Published: (2022-10-01)

Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
by: Misato Ogata, et al.
Published: (2020-01-01)

Biomarkers of Trifluridine-Tipiracil Efficacy
by: Ioannis A. Voutsadakis
Published: (2021-11-01)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
by: Naoki Takahashi, et al.
Published: (2023-08-01)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
by: Daisuke Kotani, et al.
Published: (2019-12-01)

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
by: Keigo Chida, et al.
Published: (2021-04-01)

Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
by: Kotoe Oshima, et al.
Published: (2022-01-01)

Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer
by: Kotoe Oshima, et al.
Published: (2022-01-01)

Trifluridine and Tipiracil Hydrochloride Combination-Induced Interstitial Pneumonia: A Case Report
by: Nakazawa S, et al.
Published: (2024-02-01)

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
by: Mateusz Malik, et al.
Published: (2021-10-01)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
by: Maria Alsina, et al.
Published: (2019-09-01)

Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
by: Puthiamadathil JM, et al.
Published: (2017-10-01)

Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer
by: Toshiki Masuishi, et al.
Published: (2019-11-01)

A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer
by: Jiayun Zou, et al.
Published: (2023-12-01)

Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
by: Philip Q. Ding, et al.
Published: (2022-12-01)

Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
by: Pilar García-Alfonso, et al.
Published: (2021-09-01)

RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer
by: Anna Koumarianou, et al.
Published: (2023-04-01)

Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer
by: Celso Abdon Lopes de Mello, et al.
Published: (2022-12-01)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
by: Celia Lara-Morga, et al.
Published: (2023-04-01)

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis
by: Takayuki Yoshino, et al.
Published: (2023-01-01)

Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis
by: Daniel Sur, et al.
Published: (2022-10-01)

Efficacy and tolerability of trifluridine/tipiracil in patients with refractory metastatic colorectal cancer at the general hospital of Šibenik-Knin country
by: Lana Jajac-Bručić, et al.
Published: (2021-01-01)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
by: Meng-Che Hsieh, et al.
Published: (2022-05-01)

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
by: Timothy Price, et al.
Published: (2020-05-01)

Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil
by: Itaru Hashimoto, et al.
Published: (2023-05-01)

Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience
by: Daniel Tong, et al.
Published: (2021-06-01)

Severe pancytopenia caused by trifluridine/tipiracil in patients with metastatic colorectal cancer and an impaired renal function: A case report
by: Masatsune Shibutani, et al.
Published: (2022-03-01)

Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme
by: Timothy Iveson, et al.
Published: (2020-02-01)

The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis
by: M.João de Sousa, et al.
Published: (2022-01-01)

Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer
by: M. Yu. Fedyanin, et al.
Published: (2020-12-01)

Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting
by: Mohamed ELBassiouny
Published: (2023-03-01)

Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer
by: Stefan Kasper, et al.
Published: (2018-11-01)

Dramatic Response in a Patient with Metastatic Gastric Cancer Using Trifluridine/Tipiracil after Rapid Disease Progression while on Nivolumab
by: Kazuki Nozawa, et al.
Published: (2020-11-01)

Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
by: Ana Fernández Montes, et al.
Published: (2021-07-01)

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
by: G. Sommerhäuser, et al.
Published: (2022-07-01)

Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study
by: Mamiko Shiroyama, et al.
Published: (2023-10-01)